由本刊编辑从本刊精选的重要文章

Q2 Biochemistry, Genetics and Molecular Biology

Clinical and Vaccine Immunology Pub Date : 2017-10-01 DOI:10.1128/cvi.00257-17

{"title":"由本刊编辑从本刊精选的重要文章","authors":"","doi":"10.1128/cvi.00257-17","DOIUrl":null,"url":null,"abstract":"The human hepatitis B virus polymerase (hPOL) is central to viral replication and therefore a therapeutic target. The inability to produce large quantities of recombinant hPOL has impeded structural studies of this protein. Vörös et al. (p. 2584 –2599) developed procedures to express high yields of soluble, active recombinant hPOL constructs in Escherichia coli. This advance enabled the first structural and biophysical characterizations of hPOL. The findings provide new insights into hPOL structure and function and may accelerate drug discovery for hepatitis B virus.","PeriodicalId":10271,"journal":{"name":"Clinical and Vaccine Immunology","volume":"145 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Articles of Significant Interest Selected from This Issue by the Editors\",\"authors\":\"\",\"doi\":\"10.1128/cvi.00257-17\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The human hepatitis B virus polymerase (hPOL) is central to viral replication and therefore a therapeutic target. The inability to produce large quantities of recombinant hPOL has impeded structural studies of this protein. Vörös et al. (p. 2584 –2599) developed procedures to express high yields of soluble, active recombinant hPOL constructs in Escherichia coli. This advance enabled the first structural and biophysical characterizations of hPOL. The findings provide new insights into hPOL structure and function and may accelerate drug discovery for hepatitis B virus.\",\"PeriodicalId\":10271,\"journal\":{\"name\":\"Clinical and Vaccine Immunology\",\"volume\":\"145 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Vaccine Immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1128/cvi.00257-17\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Vaccine Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1128/cvi.00257-17","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}

引用次数: 0

摘要

人类乙型肝炎病毒聚合酶(hPOL)是病毒复制的核心，因此是一个治疗靶点。无法产生大量重组hPOL阻碍了该蛋白的结构研究。Vörös等人(p. 2584 -2599)开发了在大肠杆菌中表达高产量可溶性、活性重组hPOL构建物的程序。这一进展首次实现了hPOL的结构和生物物理表征。这些发现为hPOL的结构和功能提供了新的见解，并可能加速乙型肝炎病毒药物的开发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Articles of Significant Interest Selected from This Issue by the Editors

The human hepatitis B virus polymerase (hPOL) is central to viral replication and therefore a therapeutic target. The inability to produce large quantities of recombinant hPOL has impeded structural studies of this protein. Vörös et al. (p. 2584 –2599) developed procedures to express high yields of soluble, active recombinant hPOL constructs in Escherichia coli. This advance enabled the first structural and biophysical characterizations of hPOL. The findings provide new insights into hPOL structure and function and may accelerate drug discovery for hepatitis B virus.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical and Vaccine Immunology 医学-传染病学

CiteScore

2.88

自引率

0.00%

发文量

审稿时长

1.5 months

期刊介绍： Cessation. First launched as Clinical and Diagnostic Laboratory Immunology (CDLI) in 1994, CVI published articles that enhanced the understanding of the immune response in health and disease and after vaccination by showcasing discoveries in clinical, laboratory, and vaccine immunology. CVI was committed to advancing all aspects of vaccine research and immunization, including discovery of new vaccine antigens and vaccine design, development and evaluation of vaccines in animal models and in humans, characterization of immune responses and mechanisms of vaccine action, controlled challenge studies to assess vaccine efficacy, study of vaccine vectors, adjuvants, and immunomodulators, immune correlates of protection, and clinical trials.